GlycoMASH aims to develop a blood test that can detect liver damage before it becomes life-threatening.
Liver fibrosis, often observed in fatty liver disease, progresses silently and affects millions globally. People with type 2 diabetes (T2D) are especially vulnerable, of which 65% have fatty liver disease and around 15% progress to advanced liver fibrosis. Current diagnostic tools are either invasive, inaccurate, or inaccessible, leading to late diagnoses and costly treatments like liver transplants.
Our solution is a non-invasive blood test that detects liver fibrosis at its earliest stage using a novel biomarker- a sugar-based signature found in blood proteins. This test can be performed using blood or dried blood spots, making it scalable and suitable for screening of patients with type 2 diabetes at primary care.
By identifying liver fibrosis early, especially in high-risk groups like T2D patients, we can initiate timely interventions, ranging from lifestyle changes to medication, which will improve patient outcomes. Early detection means fewer hospitalizations and liver transplants, saving millions in long-term care expenses.
Within the Biotech Booster program, we aim to validate the marker in larger clinical cohorts, optimize the test for clinical use, and develop a business and regulatory strategy for integration into routine care.
